| Popis: |
Background Β-D glucan (BDG) assay is a noninvasive test for presumptive diagnosis of invasive fungal infections (IFI). The utility of BDG assay and cut off values for positive, intermediate or negative test has been primarily studied in patients with hematological malignancies. However, the role of BDG in solid-organ transplant (SOT) recipients is not well described. The aim of this study was to evaluate the utility of serum BDG assay for IFI diagnosis in SOT recipients. Methods We retrospectively reviewed 200 patients who underwent SOT at Mayo Clinic and had BDG assay done for suspected IFI between January 1, 2013 and April 1, 2018. IFI cases were classified as proven, probable, and possible using EORTC/MSG criteria. Cases where BDG assay was used for treatment response follow-up or where results were inconclusive were excluded. BDG assay was performed at Viracor Eurofins Clinical Diagnostics lab. For the purpose of this study, a value of ≥80 pg/mL was considered positive and |
